Last 18.38 GBp
Change Today +0.75 / 4.26%
Volume 79.7K
BXP On Other Exchanges
Symbol
Exchange
London
Frankfurt
OTC US
As of 1:07 PM 10/30/14 All times are local (Market data is delayed by at least 15 minutes).

beximco pharmaceuti-gdr regs (BXP) Snapshot

Open
18.75 GBp
Previous Close
17.63 GBp
Day High
18.75 GBp
Day Low
18.38 GBp
52 Week High
09/23/14 - 20.38 GBp
52 Week Low
07/31/14 - 12.13 GBp
Market Cap
67.6M
Average Volume 10 Days
20.4K
EPS TTM
--
Shares Outstanding
367.9M
EX-Date
05/14/14
P/E TM
--
Dividend
0.01 GBp
Dividend Yield
4.15%
Current Stock Chart for BEXIMCO PHARMACEUTI-GDR REGS (BXP)

Related News

No related news articles were found.

beximco pharmaceuti-gdr regs (BXP) Related Businessweek News

No Related Businessweek News Found

beximco pharmaceuti-gdr regs (BXP) Details

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceuticals formulation products. Its formulation products comprise intravenous fluids and active pharmaceutical ingredients. The company offers its products covering various therapeutic categories, including antibiotics, gastro-intestinal, respiratory, analgesics and antipyretic, cardiovascular, anti-diabetics, allergic disorders, anti-infectives, central nervous system, cough and cold, endocrine, eye care, musculoskeletal, oncology, skin care, and vitamin and mineral supplements. It offers its products in various dosage forms, such as capsules, tablets, syrups, suspensions, injectables, sterile ophthalmic drops, nasal sprays, creams, ointments, intravenous fluids, metered dose inhalers, dry powder inhalers, suppositories, lyophilized injectables, prefilled syringes, etc. The company also provides contract manufacturing services for multinational and generic pharmaceutical companies. Beximco Pharmaceuticals Limited has a contract manufacturing agreement with GlaxoSmithKline for producing metered dose inhaler product. The company sells its products to retail outlets, medical institutions, and other pharmaceutical manufacturers in Bangladesh, Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia, Myanmar, Mauritius, Kenya, Ghana, Nigeria, Pacific Island, Latin and Central American countries, the Middle East, Central Asia, Singapore, Malaysia, the Philippines, Hong Kong, Germany, and Austria. Beximco Pharmaceuticals Limited was founded in 1976 and is headquartered in Dhaka, Bangladesh.

3,000 Employees
Last Reported Date: 07/24/14
Founded in 1976

beximco pharmaceuti-gdr regs (BXP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

beximco pharmaceuti-gdr regs (BXP) Key Developments

Beximco Pharmaceuticals Limited Announces Unaudited Earnings Results for the Second Quarter and Half Year Ended June 30, 2014; Provides Earnings Guidance for 2014

Beximco Pharmaceuticals Limited announced unaudited earnings results for the second quarter and half year ended June 30, 2014. For the quarter, the company reported net sales revenue of BDT 2,746,012,000 against BDT 2,703,345,000 a year ago. Profit from operations was BDT 632,661,000 against BDT 619,263,000 a year ago. Profit before tax was BDT 613,636,000 against BDT 619,263,000 a year ago. Profit after tax was BDT 394,489,000 or BDT 1.07 adjusted per share against BDT 375,577,000 or BDT 1.02 adjusted per share a year ago. For the half year, the company reported net sales revenue of BDT 4 5,322,272,000 against BDT 4,966,358,000 a year ago. Profit from operations was BDT 1,132,748,000 against BDT 1,048,097,000 a year ago. Profit before tax was BDT 1,018,515,000 against BDT 955,616,000 a year ago. Profit after tax was BDT 724,273,000 or BDT 1.97 adjusted per share against BDT 658,504,000 or BDT 1.79 adjusted per share a year ago. Net cash generated from operating activities was BDT 849,165,000 against BDT 833,035,000 a year ago. Acquisition of Property, Plant and Equipment was BDT 694,356,000 against BDT 212,249,000 a year ago. Intangible assets were BDT 41,495,000 against BDT 21,571,000 a year ago. Net operating cash flow per share was BDT 2.31 against BDT 2.38 a year ago. Net asset value per share was BDT 54.68 against BDT 54.31 a year ago. The company is confident that the it will continue to perform well during the remaining period to achieve its operational and financial targets for the year 2014.

Beximco Pharmaceuticals Limited Announces Cash Dividend

Beximco Pharmaceuticals Limited announced that the cash dividend of 10% of the nominal value per ordinary share/GDR, BDT 1 per ordinary share/GDR, for the year 2013, approved by its shareholders in the annual general meeting of the company held on June 21, 2014, has been deposited with the custodian bank in Dhaka for onward credit to respective GDR holders' accounts.

Beximco Pharmaceuticals Limited Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Beximco Pharmaceuticals Limited announced unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net sales revenue of BDT 2,576,260,000 against BDT 2,263,013,000 a year ago. Profit from operations was BDT 500,087,000 against BDT 428,834,000 a year ago. Profit before tax was BDT 404,879,000 against BDT 383,459,000 a year ago. Profit after tax was BDT 329,784,000 against BDT 282,927,000 a year ago. Earnings per share were BDT 0.94 against BDT 0.81 a year ago. Net cash generated from operating activities was BDT 295,538,000 against BDT 230,250,000 a year ago. Acquisition of property, plant and equipment was BDT 212,106,000 against BDT 69,717,000 a year ago. Intangible assets were BDT 7,265,000 against BDT 16,010,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BXP:LN 18.38 GBp +0.75

BXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BXP.
View Industry Companies
 

Industry Analysis

BXP

Industry Average

Valuation BXP Industry Range
Price/Earnings 5.5x
Price/Sales 0.7x
Price/Book 0.4x
Price/Cash Flow 5.5x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BEXIMCO PHARMACEUTI-GDR REGS, please visit www.beximco-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.